ANI Pharmaceuticals (ANIP) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.21
- EPS estimate
- $2.04
- EPS surprise
- +8.20%
- Revenue surprise
- +2.27%
- Revenue
- $266.0M
- Revenue estimate
- $260.1M
- Reported
- Aug 7, 2026
ANI Pharmaceuticals reported Q2 2026 results on August 7, 2026. Earnings per share came in at $2.21, ahead of the $2.04 estimate by 8.20%. Revenue was $266.0 million, about 2% above the $260.1 million consensus and the highest in the table. Compared with Q2 2025, EPS rose about 23% from $1.80 and revenue rose about 26% from $211.4 million.
The longer record shows strong growth. Annual EPS rose from $1.41 in 2022 to $4.72 in 2023, $5.20 in 2024 and $7.87 in 2025. Annual revenue grew from $316.4 million to $883.4 million over the same years. The first half of 2026 adds up to $4.26 per share, about 22% more than the same period a year earlier. The highest quarterly EPS in the table was $2.33 in Q4 2025, and the only loss was Q1 2022, at $0.12 per share. ANI beat EPS estimates in 17 of the last 20 quarters, including every quarter since Q3 2022.
ANI has reported third-quarter results between November 1 and November 9 in each of the past five years. That points to early November 2026 for the next report. It will show whether revenue keeps growing from the Q2 level.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $2.04 | $2.21 | +8.20% | $266.0M | SEC |
| Q1 2026 | May 8, 2026 | $1.30 | $2.05 | +57.84% | $237.5M | SEC |
| Q4 2025 | Feb 27, 2026 | $1.98 | $2.33 | +17.55% | $247.1M | SEC |
| Q3 2025 | Nov 7, 2025 | $1.77 | $2.04 | +15.25% | $227.8M | SEC |
| Q2 2025 | Aug 8, 2025 | $1.41 | $1.80 | +28.05% | $211.4M | SEC |
| Q1 2025 | May 9, 2025 | $1.38 | $1.70 | +22.97% | $197.1M | SEC |
| Q4 2024 | Feb 28, 2025 | $1.44 | $1.63 | +13.59% | $190.6M | SEC |
| Q3 2024 | Nov 8, 2024 | $1.09 | $1.34 | +23.39% | $148.3M | SEC |
| Q2 2024 | Aug 6, 2024 | $0.95 | $1.02 | +7.37% | $138.0M | SEC |
| Q1 2024 | May 10, 2024 | $1.00 | $1.21 | +21.49% | $137.4M | SEC |
| Q4 2023 | Feb 29, 2024 | $0.86 | $1.00 | +16.96% | $131.7M | SEC |
| Q3 2023 | Nov 8, 2023 | $0.84 | $1.27 | +50.60% | $131.8M | SEC |
| Q2 2023 | Aug 9, 2023 | $0.67 | $1.28 | +91.99% | $116.5M | SEC |
| Q1 2023 | May 8, 2023 | $0.35 | $1.17 | +232.39% | $106.8M | SEC |
| Q4 2022 | Mar 9, 2023 | $0.67 | $0.76 | +13.10% | $94.2M | SEC |
| Q3 2022 | Nov 9, 2022 | $0.55 | $0.64 | +15.84% | $83.8M | — |
| Q2 2022 | Aug 8, 2022 | $0.22 | $0.13 | −40.91% | $73.9M | — |
| Q1 2022 | May 10, 2022 | $0.09 | −$0.12 | −228.62% | $64.5M | — |
| Q4 2021 | Mar 15, 2022 | $0.74 | $0.54 | −27.03% | $60.9M | — |
| Q3 2021 | Nov 1, 2021 | $0.70 | $1.01 | +44.29% | $52.1M | — |
Quarterly revenue
Frequently asked questions
When did ANI Pharmaceuticals (ANIP) last report earnings?
ANI Pharmaceuticals last reported on Aug 7, 2026, covering fiscal Q2 2026.
Did ANIP beat earnings estimates?
Yes. ANI Pharmaceuticals reported EPS of $2.21 for Q2 2026 against a $2.04 estimate — a 8.20% beat.
How much revenue did ANIP report last quarter?
ANI Pharmaceuticals reported $266.0M in revenue for Q2 2026, against a consensus estimate of $260.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.